10.22376/ijpbs.2019.10.1.p1-12 Volume 4 Issue 4 2013 (October - December) Linezolid is one of the few effective ways to treat Methicillin Resistant lessThan i greaterThan Staphylococcus aureus lessThan /i greaterThan infections. However resistance has been reported recently. Hence we conducted this study to determine the methicillin susceptibility of lessThan i greaterThan Staphylococci lessThan /i greaterThan isolated from blood culture samples and to know their susceptibility to Linezolid. A total of 252 lessThan i greaterThan Staphylococci lessThan /i greaterThan were subjected to antibiotic susceptibility testing by Kirby- Bauer disk diffusion method; MRSA was detected by using cefoxitin disk (30µg) and linezolid (30µg) was included to know susceptibility. Methicillin resistance was observed in 53 (69.74%) of the lessThan i greaterThan Staphylococcus aureus lessThan /i greaterThan and 131(74.43%) of the Coagulase negative lessThan i greaterThan Staphylococci lessThan /i greaterThan . Linezolid resistance was observed in 3 (5.66%) of the MRSA and 2 (1.53 %) of the Methicillin Resistant lessThan i greaterThan Coagulase Negative Staphylococci lessThan /i greaterThan . Linezolid is the therapeutic choice in methicillin resistant lessThan i greaterThan Staphylococci lessThan /i greaterThan as it could be administered orally and comparatively cheaper than glycopeptides. So this emergence of resistance may pose problem in the treatment. LYRA.P R, ANURADHA.K, SHILPA. A AND VENKATESHA. D Linezolid resistance, MRSA, LRSA 1085-1090